Mounjaro®
Starting from £179.99/mo
Start journey Learn moreReduced appetite is one of the most commonly reported experiences on Wegovy (semaglutide). For many people, it's the medicine working as expected — the GLP-1 receptor it activates is directly involved in signalling fullness to the brain. But when appetite drops sharply or nearly disappears, it raises a real question: should you eat anyway, eat less, or be concerned? The answer depends on several factors your prescriber is best placed to help you weigh up, because semaglutide is a prescription-only medicine and the right response is personal. These pages explore the key considerations so you can have a more informed conversation with your clinical team.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mostly, yes. Wegovy's active ingredient, semaglutide, attaches to GLP-1 receptors in the gut and brain. One result is a meaningful reduction in hunger signals, and if you want to understand how Wegovy curbs appetite and the mechanisms behind that effect, there is a dedicated page covering it in detail. In the STEP 1 trial published in the New England Journal of Medicine, participants on semaglutide 2.4mg lost an average of around 15% of body weight over 68 weeks, and that reduction in body weight is closely tied to a sustained fall in appetite and calorie intake, not just metabolic change.
So if you sit down to lunch and the plate holds no appeal, that is often the medicine doing its job. The clinical goal, though, is not to stop eating. It is to eat less, eat better, and let the body draw on stored fat for energy. A useful way to frame it: reduced appetite is the lever; what you choose to eat while the lever is pulled is where the work still happens.
That said, there is a difference between a gradual reduction in appetite and a sudden or total disappearance of hunger. The first is expected and manageable. The second deserves attention.
A question our prescribers hear most weeks is some version of: "I'm barely eating anything, is that okay?" The honest answer is that it depends on what "barely anything" means in practice.
Eating too little protein over weeks accelerates the loss of lean muscle mass alongside fat. Muscle matters for metabolism, mobility and long-term weight maintenance, so protecting it matters even when appetite is low. Guidance accompanying GLP-1 treatment consistently recommends prioritising protein at each meal, staying well hydrated, and keeping up activity, including resistance exercise where possible. The nutrition approach that works alongside Wegovy is worth reading before you assume eating very little is fine.
Nausea is a common companion to appetite loss, particularly after a dose increase, and it usually settles within the first one to two weeks at a new level. If nausea is the main reason you cannot face food, that is likely temporary. If you are vomiting repeatedly, struggling to keep fluids down, or feeling faint, contact your prescriber or 111 promptly, dehydration from severe vomiting can affect kidney function and is something clinicians need to know about.
The NHS medicines page for semaglutide advises that if side effects are severe or persistent, you should speak to your GP or prescriber rather than adjusting your dose yourself. That includes appetite loss severe enough to stop you eating nutritious meals.
Some people start Wegovy and find the appetite reduction they expected simply hasn't arrived. This is a separate situation from the question this page focuses on, but it comes up enough to mention briefly. If you feel no appetite suppression on Wegovy at all, the factors to consider include dose level, injection technique, storage conditions and individual response. That topic has its own detailed page.
For those at the other end, where appetite disappears on Wegovy entirely and eating feels forced, the decision framework is simpler: eat small, eat often, prioritise protein and vegetables, and keep drinking water. If that approach is not working and meals feel impossible, reach out to your prescriber. Slowing the titration pace is a legitimate clinical option; it is not a failure.
The goal is not a clean plate. It is adequate nutrition inside a lower calorie intake. A few things tend to help in practice. Smaller portions eaten more frequently are easier to manage than standard meal sizes. Protein-dense foods (eggs, fish, Greek yoghurt, legumes) take up less room but do more nutritional work than high-carbohydrate options. Cold foods are often more tolerable than hot ones when nausea sits alongside appetite loss.
Cost of treatment is sometimes a factor in decisions about whether to continue or adjust. You can compare Wegovy costs and what is included at different services, it is worth understanding what aftercare support you are paying for alongside the medicine itself, because access to clinical review when things feel off is part of the value.
If you are weighing whether Wegovy is the right treatment for your situation, or want to discuss how your current response compares to what is expected, speaking to our prescribers through a free consultation is a straightforward next step. They review every case personally (no automated triage) and are available seven days a week for aftercare questions once treatment begins.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.